Company intelligence / Profile preview

Wellnature Biotech

Taipei, Taiwan

Ownership: Private
Development stage: Other

Overview

Wellnature Biotech is a Taiwan-based biotechnology company specializing in the research and development of botanical drugs and high-end functional health products. The company focuses on leveraging the therapeutic properties of Antrodia cinnamomea, a rare medicinal fungus endemic to Taiwan, to treat liver-related diseases. Their lead candidate, WNB01, is being evaluated in clinical trials for indications such as hepatocellular carcinoma and liver fibrosis. Wellnature integrates proprietary cultivation technologies with pharmaceutical-grade extraction processes to ensure the consistency and efficacy of its botanical formulations.

Therapeutic areas: OncologyGastroenterology
Modalities: Botanical drugSmall molecule
Industry: Biotech

Beyond the preview

Go deeper on Wellnature Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Wellnature Biotech.

Explore the full profile